


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-146. (Canceled)

Claim 147. (Currently Amended) A substituted 1- and 2-naphthol Mannich base of formula I



I

wherein

$R^1 = CH(R^9) N(R^{10})(R^{11})$ and $R^2 = OR^{12}$ or

$R^1 = OR^{12}$ and $R^2 = CH(R^9) N(R^{10})(R^{11})$, and in each case the radicals

R^3 to R^8 are identical or different and = H, F, Cl, Br, CF_3 , CN, NO_2 , SO_2NH_2 , SO_2NHR^{13} , NHR^{13} , SR^{15} , OR^{16} , $CO(OR^{20})$, $CH_2CO(OR^{21})$, $CO(R^{22})$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^9 denotes an aryl radical, a heteroaryl radical or an alkyl radical without an acid proton in the α -position,

R^{10} , R^{11} are identical or different and denote a branched or unbranched, saturated or unsaturated, unsubstituted or at least monosubstituted C_{1-6} -alkyl radical or an unsubstituted or at least monosubstituted phenyl, benzyl or phenethyl radical, or

R^{10} and R^{11} together denote $(CH_2)_2O(CH_2)_2$ or $(CH_2)_n$, wherein $n = 3$ or 6 ,

$R^{12} = H$, COR^{22} , a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{13} = H$, COR^{14} , a C_{1-10} -alkyl, an aryl radical, heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{14} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{15} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{16} = H$, $CO(R^{17})$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{17} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{18} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{20} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{21} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{22} = H$, $NHNH_2$, NHR^{18} , a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

or a racemate, enantiomer, diastereomer, a corresponding base of a physiologically tolerated acid or a corresponding salt of physiologically tolerated acid thereof,

excluding

the racemates of the compounds in which the radical $R^1 = CH(R^9)N(R^{10})(R^{11})$ and $R^2 =$
 OR^{12} and in each case

the radicals R^3 to R^8 and $R^{12} = H$, the radical $R^9 =$ phenyl, 4-methoxyphenyl, 4-dimethylaminophenyl, 4-hydroxy-2,3-di-tert-butylphenyl, 2,3-dihydrobenzodioxane, 4-nitrophenyl or benzo-1,3-dioxole and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$,

or

the radicals R^3 to R^8 and $R^{12} = H$, the radical $R^9 =$ phenyl and the two radicals R^{10} and R^{11} each $= CH_3$, C_2H_5 or $n-C_3H_7$,

or

the radicals R^3 to R^8 each denote H, the radical $R^{12} = CH_3$, the radical $R^9 =$ phenyl and
the two radicals R^{10} and R^{11} each $= CH_3$.

or

the radicals R^3 to R^8 and $R^{12} = H$, the radical $R^9 =$ 4-methoxyphenyl or benzo-1,3-dioxole and the two radicals R^{10} and R^{11} each $= CH_3$,

or

the radicals R^3 to R^5 , R^7 , R^8 , $R^{12} = H$, the radical $R^6 = Br$, the radical $R^9 = 4$ -hydroxy-3,5-di-tert-butylphenyl and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$,

or

the radicals R^3 to R^8 and $R^{12} = H$, the radical $R^9 = \text{phenyl}$ and the radicals R^{10} and R^{11} each $= CH_3$ as the hydrochloride,

or

the radicals R^3 to R^8 and $R^{12} = H$, the radical $R^9 = \text{thiophene}$ and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$,

or

the radicals R^3 to $R^8 = H$, the radical $R^{12} = CH_3$, the radical $R^9 = \text{thiophene}$, 4-methoxyphenyl or 3,4-dimethoxyphenyl and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$,

(+) -1-(α -N,N-dimethylaminobenzyl)-2-naphthol and the corresponding tartrate,

(-) -1-(α -N,N-dimethylaminobenzyl)-2-naphthol and the corresponding tartrate, and

(-)-[(2-methoxynaphth-1-yl)benzyl]-dimethylamine and the

racemates of the compounds in which the radicals $R^1 = OR^{12}$ and $R^2 = CH(R^9)N(R^{10})(R^{11})$ and in each case

the radicals R^3 to R^8 and $R^{12} = H$, the radical $R^9 = \text{phenyl}$ or 2-nitrophenyl and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$,

or

the radicals R^3 to R^8 and $R^{12} = H$, the radical $R^9 = \text{phenyl}$, the radical $R^{10} = CH_3$ and the radical $R^{11} = C_6H_{11}$ or the radicals R^{10} and R^{11} each $= CH_3$,

or

the radicals R^3 to R^6 , R^8 , $R^{12} = H$, the radical $R^7 = CH_3$, the $R^9 = \text{phenyl}$ or 4-methoxyphenyl and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$,

or

the radicals R^3 , R^4 , R^6 , R^8 ,] and $R^{12} = H$, the radicals R^5 and $R^7 = CH_3$, the radical $R^9 = 4\text{-methoxyphenyl}$ and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$,

or

the radicals R^3 to R^8 , $R^{12} = H$, the radical $R^9 = \text{phenyl}$ and the radicals R^{10} and R^{11} together $= (CH_2)_2O(CH_2)_2$ as the hydrochloride.

Claim 148. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents H .

Claim 149. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents a C_{1-6} -alkyl radical.

Claim 150. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents an aryl radical bonded via a C_{1-2} -alkylene group.

Claim 151. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents F, Cl or Br.

Claim 152. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents SO_2NH_2 .

Claim 153. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents NHR^{13} .

Claim 154. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents $CO(R^{22})$.

Claim 155. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents OR^{16} .

Claim 156. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^3 , R^4 , R^5 , R^6 , R^7 or R^8 represents $CO(OR^{20})$.

Claim 157. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^9 denotes an unsubstituted phenyl radical or a phenyl radical which is at least monosubstituted by C_{1-4} -alkyl, C_{1-3} -alkoxy, halogen, CF_3 , CN, O-phenyl or OH.

Claim 158. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein at least one of the radicals R^{10} or R^{11} represents a saturated, unsubstituted or at least monosubstituted C_1 - C_6 -alkyl radical and the other remaining radical R^{10} or R^{11} and the R^{12} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 159. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{12} represents H and the radicals R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 160. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{12} represents a C_1 - C_6 -alkyl radical and the radicals R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 161. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{12} represents an aryl radical bonded via a C_1 - C_2 -alkylene group and the radicals R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 162. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{13} represents a H and the radicals R^{14} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 163. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{13} represents a C_{1-6} -alkyl radical and the radicals R^{14} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 164. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{13} represents an aryl radical bonded via a C_{1-2} -alkylene group and the radicals R^{14} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 165. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{14} represents a C_{1-6} -alkyl radical and the radicals R^{15} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 166. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{14} represents an aryl radical bonded via a C_{1-2} -alkylene group and the radicals R^{15} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 167. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{15} represents a C_{1-6} -alkyl radical and the radicals R^{16} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 168. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{15} represents an aryl radical bonded via a C_{1-2} -alkylene group and the radicals R^{16} to R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 169. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{16} represents a C_{1-6} -alkyl radical and the radicals R^{17} , R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 170. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{16} represents an aryl radical bonded via a C_{1-2} -alkylene group and the radicals R^{17} , R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 171. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{16} represents H and the radicals R^{17} , R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 172. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{16} represents $CO(R^{17})$ and the radicals R^{17} , R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 173. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{17} represents a C_{1-6} -alkyl radical and the radicals R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 174. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{17} represents an aryl radical bonded via a C_{1-2} -alkylene group and the radicals R^{18} and R^{20} to R^{22} have the meaning according to Claim 147.

Claim 175. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R¹⁷ represents a phenyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy and the radicals R¹⁸ and R²⁰ to R²² have the meaning according to Claim 147.

Claim 176. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R¹⁸ represents a C₁₋₆-alkyl radical and the radicals R²⁰ to R²² have the meaning according to Claim 147.

Claim 177. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R¹⁸ represents an aryl radical bonded via a C₁₋₂-alkylene group and the radicals R²⁰ to R²² have the meaning according to Claim 147.

Claim 178. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R¹⁸ represents a phenyl radical or a naphthyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy, and the radicals R²⁰ to R²² have the meaning according to Claim 147.

Claim 179. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R²⁰ represents a C₁₋₆-alkyl radical and the radicals R²¹ and R²² have the meaning according to Claim 147.

Claim 180. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{20} represents an aryl radical bonded via a C_{1-2} -alkylene group and the radicals R^{21} and R^{22} have the meaning according to Claim 147.

Claim 181. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{20} represents H and the radicals R^{21} and R^{22} have the meaning according to Claim 147.

Claim 182. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{20} represents a phenyl radical which is optionally substituted by F, Cl, Br, C_{1-4} -alkyl or C_{1-3} -alkoxy and the radicals R^{21} and R^{22} have the meaning according to Claim 147.

Claim 183. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{21} represents H and the radical R^{22} has the meaning according to Claim 147.

Claim 184. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{21} represents a C_{1-6} -alkyl radical and the radical R^{22} has the meaning according to Claim 147.

Claim 185. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{21} represents an aryl radical bonded via a C_{1-2} -alkylene group and the radical R^{22} has the meaning according to Claim 147.

Claim 186. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{22} represents H.

Claim 187. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{22} represents a C_{1-6} -alkyl radical.

Claim 188. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{22} represents an aryl radical bonded via a C_{1-2} -alkylene group.

Claim 189. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147, wherein the radical R^{22} represents $NHNH_2$, NHR^{18} or a phenyl radical which is optionally substituted by F, Cl, Br, C_{1-4} -alkyl or C_{1-3} -alkoxy.

Claim 190. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 147 wherein the Mannich base is


6-(dimethylaminophenylmethyl)-5-hydroxy-naphthalene-1-sulfonic acid amide,
4-amino-2-(dimethylaminophenylmethyl)-naphthalen-1-ol,

4-(dimethylaminophenylmethyl)-3-hydroxy-naphthalene-2-carboxylic acid hydrazide,
4-(dimethylaminophenylmethyl)-3-hydroxy-naphthalene-2-carboxylic acid methyl
ester,
4-(dimethylamino-phenyl-methyl)-3-hydroxy-naphthalene-2-carboxylic acid,
4-(dimethylaminophenylmethyl)-3-hydroxy-naphthalene-2-carboxylic acid phenyl
ester,
[5-(dimethylaminophenylmethyl)-6-hydroxynaphthalen-2-yl]-phenylmethanone,
3-amino-1-(dimethylaminophenylmethyl)-naphthalen-2-ol,
4-(dimethylaminophenylmethyl)-3-hydroxynaphthalene-2-carboxylic acid (2-
methoxy-phenyl)-amide,
4-(dimethylaminophenylmethyl)-3-hydroxy-naphthalene-2-carboxylic acid o-
tolylamide,
4-(dimethylaminophenylmethyl)-3-hydroxynaphthalene-2-carboxylic acid
naphthalen-1-ylamide,
4-(dimethylaminophenylmethyl)-3-hydroxy-7-methoxynaphthalene-2-carboxylic
acid,
5-(dimethylaminophenylmethyl)-6-hydroxynaphthalene-2-carboxylic acid,
1-(dimethylaminophenylmethyl)-7-methoxynaphthalen-2-ol,
1-(dimethylaminophenylmethyl)-6-methoxynaphthalen-2-ol,
5-(dimethylaminophenylmethyl)-6-hydroxynaphthalene-1-carboxylic acid,
4-(dimethylaminophenylmethyl)-3-hydroxy-7-methoxynaphthalene-2-carboxylate
sodium salt,

4-chloro-2-(morpholin-4-yl-o-tolylmethyl)-naphthalen-1-ol,
4-chloro-2-[(2,3-dimethoxyphenyl)-morpholin-4-yl-methyl]-naphthalen-1-ol,
5-amino-2-[(2,3-dimethoxyphenyl)-morpholin-4-yl-methyl]-naphthalen-1-ol,
7-methoxy-1-(morpholin-4-yl-o-tolylmethyl)-naphthalen-2-ol,
1-[(2,3-dimethoxyphenyl)-morpholin-4-yl-methyl]-7-methoxynaphthalen-2-ol,
6-bromo-1-[(2-methoxyphenyl)-morpholin-4-yl-methyl]-naphthalen-2-ol,
6-hydroxy-5-[(2-methoxyphenyl)-morpholin-4-yl-methyl]-naphthalene-1-carboxylic
acid,
7-methoxy-1-[(2-methoxyphenyl)-morpholin-4-yl-methyl]-naphthalen-2-ol,
6-methoxy-1-[(2-methoxyphenyl)-morpholin-4-yl-methyl]-naphthalen-2-ol,
5-chloro-2-[dimethylamino-(2-methoxyphenyl)-methyl]-naphthalen-1-ol,
{[1-(4-methoxybenzyloxy)-naphthalen-2-yl]-phenylmethyl}-dimethylamine,
{[2-(4-methoxybenzyloxy)-naphthalen-1-yl]-phenylmethyl}-dimethylamine,
4-methoxybenzoic acid 1-(dimethylaminophenylmethyl)-naphthalen-2-yl ester,
2-chlorobenzoic acid 1-(dimethylaminophenylmethyl)-naphthalen-2-yl ester,
1-(morpholin-4-yl-phenylmethyl)-naphthalen-2-ol.


Claim 191. (Previously Presented) A process for the preparation of substituted 1- and 2-naphthol Mannich bases of formula I according to Claim 147, wherein in which the radical R^{12} represents H and the radicals R^1 to R^{11} , R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to formula I, said process comprising :

reacting one or more aromatic aldehyde compounds, heteroaromatic aldehyde compounds or aliphatic aldehyde compounds of formula II




II

in which R⁹ has the meaning according to formula I, in solution in the presence of a base with one or more secondary amines of formula III




III

in which R¹⁰ and R¹¹ have the meaning according to formula I,
to give one or more aminal compounds of formula IV




IV

reacting said aiminal compounds of formula IV, without further purification, with an acid chloride in an absolute solvent to give one or more iminium salts of formula V



reacting said iminium salts of formula V without further purification and in solution with one or more substituted and/or unsubstituted 1- and 2-naphthol compounds of formula VI




VI

wherein $R^1 = H$ and $R^2 = OH$ or $R^1 = OH$ and $R^2 = H$ and in each case the radicals R^3 to R^8 , R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to formula I, and the 1- and 2-naphthol Mannich bases of formula I obtained in this way in which the radical R^{12} represents H and the radicals R^1 to R^{11} , R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to formula I are purified by extraction and are isolated by conventional methods.


Claim 192. (Previously Presented) A process for the preparation of one or more substituted 1- and 2-naphthol Mannich bases of formula I according to Claim 147 wherein the radical $R^{12} = COR^{22}$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group and the radicals R^1 to R^{11} , R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to formula I, said process comprising :

reacting one or more aromatic aldehyde compounds, heteroaromatic aldehyde compounds or aliphatic aldehyde compounds of formula II




II

in which R⁹ has the meaning according to formula I in solution in the presence of a base with one or more secondary amines of formula III




III

in which R¹⁰ and R¹¹ have the meaning according to formula I,
to give one or more aminal compounds of formula IV




IV

and reacting said aminal compounds of formula IV without further purification, with an acid chloride in an absolute solvent to give iminium salts of formula V



and reacting said iminium salts of formula V without further purification and in solution with one or more substituted and/or unsubstituted 1- and 2-naphthol compounds of formula VI



wherein $R^1 = H$ and $R^2 = OH$ or $R^1 = OH$ and $R^2 = H$, and in each case the other radicals R^3 to R^{18} and R^{20} to R^{22} have the meaning according to formula I, and the 1- and 2-naphthol Mannich bases of formula I obtained in this way in which the radical R^{12} represents H and the radicals R^1 to R^{11} , R^{13} to R^{18} and R^{20} to R^{22} have the meaning according to formula I, are purified by filtration and are isolated by conventional methods.

Claim 193. (Previously Presented) The process according to Claim 192, wherein the reaction with the compounds of formula $\text{XR}^{12'}$ is carried out in dimethylformamide.

Claim 194. (Previously Presented) The process according to Claim 192, wherein $\text{X} = \text{Cl}$.

Claim 195. (Previously Presented) The process according to Claim 192, wherein the reaction with the compounds of formula $\text{XR}^{12'}$ is carried out in the presence of triethylamine or potassium tert-butyrate as a base.

Claim 196. (Previously Presented) The process according to Claim 192, wherein the compounds of formula I in which R^{12} is not H, are purified by filtration over a scavenger resin

Claim 197. (Previously Presented) The process according to Claim 191, wherein the aromatic aldehyde compounds, heteroaromatic aldehyde compounds and/or aliphatic aldehyde compounds of formula II are reacted in an organic solvent with one or more secondary amines of formula III.


Claim 198. (Previously Presented) The process according to Claim 191, wherein the aromatic aldehyde compounds, heteroaromatic aldehyde compounds and/or aliphatic

aldehyde compounds of formula II are reacted in the presence of potassium carbonate or boric acid anhydride as the base.

Claim 199. (Previously Presented) The process according to Claim 191, wherein the amination compounds of formula IV are reacted with acetyl chloride to give iminium salts of formula V.

Claim 200. (Previously Presented) The process according to Claim 191, wherein the amination compounds of formula IV are reacted in absolute diethyl ether to give iminium salts of formula V.

Claim 201. (Previously Presented) A medicament comprising, at least one substituted 1- and 2-naphthol Mannich base of formula I



I

wherein

$R^1 = CH(R^9)N(R^{10})(R^{11})$ and $R^2 = OR^{12}$

or

$R^1 = OR^{12}$ and $R^2 = CH(R^9)N(R^{10})(R^{11})$,

and in each case the radicals

R^3 to R^8 are identical or different and is H, F, Cl, Br, CF_3 , CN, NO_2 , SO_2NH_2 , SO_2NHR^{13} , NHR^{13} , SR^{15} , OR^{16} , $CO(OR^{20})$, $CH_2CO(OR^{21})$, $CO(R^{22})$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^9 denotes an aryl radical, a heteroaryl radical or an alkyl radical without an acid proton in the α -position,

R^{10} , R^{11} are identical or different and denote a branched or unbranched, saturated or unsaturated, unsubstituted or at least monosubstituted C_{1-6} -alkyl radical or an unsubstituted or at least monosubstituted phenyl, benzyl or phenethyl radical, or

R^{10} and R^{11} together denote $(CH_2)_n$, wherein $n = 3$ or 6, or $(CH_2)_2O(CH_2)_2$,

$R^{12} = H$, COR^{22} , a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{13} = H$, COR^{14} , a C_{1-10} -alkyl, an aryl radical, heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{14} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{15} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{16} = H$, $CO(R^{17})$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{17} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{18} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{20} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene

$R^{21} = H$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

$R^{22} = H$, $NHNH_2$, NHR^{18} , a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

and/or their racemates, enantiomers, diastereomers, and/or corresponding bases and/or corresponding salts of physiologically tolerated acid and optionally further active compounds and/or auxiliary substances.

Claim 202. (Previously Presented) The medicament according to Claim 201, comprising a mixture of enantiomers of at least one substituted 1-naphthol Mannich base and/or 2-naphthol Mannich base of formula I in non-equimolar amounts.

Claim 203. (Previously Presented) The medicament according to Claim 201, wherein the relative proportion of one of the enantiomers of the mixture is 5 to 45 mol % based on the mixture of enantiomers.

Claim 204. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 157, wherein the radical R⁹ is 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 2-tert-butyl-phenyl, 3-tert-butyl-phenyl, 4-tert-butylphenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-bromo-phenyl, 3-bromo-phenyl, 4-bromo-phenyl, 5-bromo-2-fluoro-phenyl, 2-chloro-4-fluoro-phenyl, 2-chloro-5-fluoro-phenyl, 2-chloro-6-fluoro-phenyl, 4-bromo-2-fluoro-phenyl, 3-bromo-4-fluoro-phenyl, 3-bromo-2-fluoro-phenyl, 2,3-dichloro-phenyl, 2,4-dichloro-phenyl, 2,5-dichloro-phenyl, 3,4-dichloro-phenyl, 2,3-dimethyl-phenyl, 2,4-dimethyl-phenyl, 2,5-dimethyl-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 2,5-dimethoxy-phenyl, 3,4-dimethoxy-phenyl, 3,4,5-trimethoxy-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoro-methyl-phenyl or 4-trifluoromethyl-phenyl radical.

Claim 205. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 157, wherein R⁹ is an unsubstituted phenyl radical.

Claim 206. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 158, wherein at least one of the radicals R¹⁰ or R¹¹ is a CH₃ radical.

Claim 207. (Previously Presented) The substituted 1- and 2-naphthol Mannich base according to Claim 178, wherein R¹⁸ is a phenyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy.

Claim 208. (Previously Presented) The process of Claim 191, wherein the aromatic aldehyde compounds, heteroaromatic aldehyde compounds or aliphatic aldehyde compounds of formula II are reacted at a temperature of from -10°C to 110°C.

Claim 209. (Previously Presented) The process of Claim 191, wherein the iminium salts of formula V are reacted in acetonitrile.

Claim 210. (Previously Presented) The process of Claim 192, wherein the aromatic aldehyde compounds, heteroaromatic aldehyde compounds and/or aliphatic aldehyde compounds of formula II are reacted at a temperature of from -10 to 110°C.

Claim 211. (Previously Presented) The process of Claim 192, wherein the iminium salts of formula V are reacted in acetonitrile.

Claim 212. (Previously Presented) The process of Claim 192, wherein the iminium compounds of formula XR¹² are reacted at a temperature of from 10 to 150°C.

Claim 213. (Previously Presented) The process of Claim 196, wherein the scavenger resin is polymer-bonded tris(2-aminoethyl)amine and/or 3-(3-mercaptophenyl)propane-amidomethylpolystyrene.

Claim 214. (Previously Presented) The process according to Claim 197, wherein the compounds are reacted in toluene.

Claim 215. (Previously Presented) The process according to Claim 192, wherein the aromatic aldehyde compounds, heteroaromatic aldehyde compounds or aliphatic aldehyde compounds of formula II are reacted in the presence of potassium carbonate or boric acid anhydride as a base.

Claim 216. (Previously Presented) The process according to Claim 192, wherein one or more aromatic aldehyde compounds, heteroaromatic aldehyde compounds, or aliphatic aldehyde compounds of formula II are reacted in an organic solvent with one or more secondary amines of formula III.

Claim 217. (Previously Presented) The process according to Claim 216, wherein the compounds are reacted in toluene.

Claim 218. (Previously Presented) The process according to Claim 189, wherein R^{22} is $NHNH_2$ or NHR^{18} .

Claim 219. (Previously Presented) The process according to Claim 192, wherein the aминаl compounds of formula IV are reacted with acetyl chloride to give iminium salts of formula V.

Claim 220. (Previously Presented) The process according to Claim 192, wherein the amination compounds of formula IV are reacted in absolute diethyl ether to give iminium salts of formula V.

Claim 221. (Previously Presented) The medicament of Claim 201, wherein R^3 to R^8 are identical or different and may be H, F, Cl, Br, SO_2NH_2 , NHR^{13} , $CO(R^{22})$, OR^{16} , $CO(OR^{20})$, a C_{1-6} -alkyl radical or an aryl radical bonded by a C_{1-2} -alkylene group.

Claim 222. (Previously Presented) The medicament of Claim 201, wherein R^3 to R^8 are identical or different and may be H, NHR^{13} , $CO(R^{22})$, OR^{16} or $CO(OR^{20})$.

Claim 223. (Previously Presented) The medicament of Claim 201, wherein R^9 is an unsubstituted phenyl radical or a phenyl radical which is at least monosubstituted by C_{1-4} -alkyl, C_{1-3} -alkoxy, halogen, CF_3 , CN, O-phenyl or OH.

Claim 224. (Previously Presented) The medicament of Claim 201, wherein R^9 is 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 2-tert-butyl-phenyl, 3-tert-butyl-phenyl, 4-tert-butyl-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-bromo-phenyl, 3-bromo-phenyl, 4-bromo-phenyl, 5-bromo-2-fluoro-phenyl, 2-chloro-4-fluoro-phenyl, 2-chloro-5-fluoro-phenyl, 2-chloro-6-fluoro-phenyl, 4-bromo-2-fluoro-phenyl, 3-bromo-4-fluoro-phenyl, 3-bromo-2-fluoro-phenyl, 2,3-dichloro-phenyl, 2,4-dichloro-

phenyl, 2,5-dichloro-phenyl, 3,4-dichloro-phenyl, 2,3-dimethyl-phenyl, 2,4-dimethyl-phenyl, 2,5-dimethylphenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 2,5-dimethoxy-phenyl, 3,4-dimethoxy-phenyl, 3,4,5-trimethoxy-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl or 4-trifluoromethyl-phenyl radical.

Claim 225. (Previously Presented) The medicament of Claim 201, wherein R^9 is an unsubstituted phenyl radical.

Claim 226. (Previously Presented) The medicament of Claim 201, wherein R^{10} and R^{11} are a saturated, unsubstituted or at least monosubstituted C_{1-6} -alkyl radical.

Claim 227. (Previously Presented) The medicament of Claim 201, wherein R^{10} and R^{11} are a CH_3 radical.

Claim 228. (Previously Presented) The medicament of Claim 201, wherein R^{12} is H, a C_{1-6} -alkyl radical or an aryl radical bonded via a C_{1-2} -alkylene group.

Claim 229. (Previously Presented) The medicament of Claim 201, wherein R^{13} is H, a C_{1-6} -alkyl radical or an aryl radical bonded via a C_{1-2} -alkylene group.

Claim 230. (Previously Presented) The medicament of Claim 201, wherein R^{13} is H.

Claim 231. (Previously Presented) The medicament of Claim 201, wherein R^{14} is a C_{1-6} -alkyl radical or an aryl radical bonded via a C_{1-2} -alkylene group.

Claim 232. (Previously Presented) The medicament of Claim 201, wherein R^{15} is a C_{1-6} -alkyl radical or an aryl radical bonded via a C_{1-2} -alkylene group.

Claim 233. (Previously Presented) The medicament of Claim 201, wherein R^{16} is H, a C_{1-6} -alkyl radical, an aryl radical bonded via a C_{1-2} -alkylene group or $CO(R^{17})$.

Claim 234. (Previously Presented) The medicament of Claim 201, wherein R^{16} is H or $CO(R^{17})$.

Claim 235. (Previously Presented) The medicament of Claim 201, wherein R^{17} is a C_{1-6} -alkyl radical, an aryl radical bonded via a C_{1-2} -alkylene group or a phenyl radical which is optionally substituted by F, Cl, Br, C_{1-4} -alkyl or C_{1-3} -alkoxy.

Claim 236. (Previously Presented) The medicament of Claim 201, wherein R^{17} is a phenyl radical which is optionally substituted by F, Cl, Br, C_{1-4} -alkyl or C_{1-3} -alkoxy.

Claim 237. (Previously Presented) The medicament of Claim 201, wherein R^{18} is a C_{1-6} -alkyl radical, an aryl radical bonded via a C_{1-2} -alkylene group or a phenyl or naphthyl radical which is optionally substituted by F, Cl, Br, C_{1-4} -alkyl or C_{1-3} -alkoxy.

Claim 238. (Previously Presented) The medicament of Claim 201, wherein R¹⁸ is a phenyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy.

Claim 239. (Previously Presented) The medicament of Claim 201, wherein R²⁰ is H, a C₁₋₆-alkyl radical, an aryl radical bonded via a C₁₋₂-alkylene group or a phenyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy.

Claim 240. (Previously Presented) The medicament of Claim 201, wherein R²⁰ is H or a phenyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy.

Claim 241. (Previously Presented) The medicament of Claim 201, wherein R²¹ is H, a C₁₋₆-alkyl radical or an aryl radical bonded via a C₁₋₂-alkylene group.

Claim 242. (Previously Presented) The medicament of Claim 201, wherein R²² is H, a C₁₋₆-alkyl radical, an aryl radical bonded via a C₁₋₂-alkylene group, NHR¹⁸ or a phenyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy.

Claim 243. (Previously Presented) The medicament of Claim 201, wherein R²² is NHR¹⁸ or a phenyl radical which is optionally substituted by F, Cl, Br, C₁₋₄-alkyl or C₁₋₃-alkoxy.

Claim 244. (Previously Presented) The medicament of Claim 201, wherein R²² is NHNH₂ or NHR¹⁸.

Claim 245. (New) The medicament of Claim 203, wherein the reactive portion of one of the enantiomers of the mixture is 10-40 mol % based on the mixture of enantiomers.

Claim 246. (Previously Presented) A process for preparing a pharmaceutical composition, said process comprising
mixing the medicament of Claim 201 with a pharmaceutically acceptable carrier or diluent.

Claim 247. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an amount effective for combating pain in a person in need thereof.

Claim 248. (Previously Presented) A method comprising
administering composition comprising at least one Mannich base of Claim 147 in an amount effective for treating inflammatory reactions in a person in need thereof.

Claim 249. (Previously Presented) A method comprising
administering a composition comprising one or more Mannich base of Claim 147 in an amount effective for treating allergic reactions to a person in need thereof.

Claim 250. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating drug and/or alcohol abuse in a person in need thereof.

Claim 251. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating diarrhea to a person in need thereof.

Claim 252. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating gastritis to a person in need thereof.

Claim 253. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating ulcers to a person in need thereof.

Claim 254. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating cardiovascular disease to a person in need thereof.

Claim 255. (Previously Presented) A method comprising

administering a composition comprising at least one Mannich base of Claim 147 in an amount effective for treating urinary incontinence to a person in need thereof.

Claim 256. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an amount effective for treating depression to a person in need thereof.

Claim 257. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an amount effective for treating shock to a person in need thereof.

Claim 258. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an amount effective for treating migraines to a person in need thereof.

Claim 259. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an amount effective for treating narcolepsy to a person in need thereof.

Claim 260. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an amount effective for reducing the weight of a person.

Claim 261. (New) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating asthma to a person in need thereof.

Claim 262. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating glaucoma to a person in need thereof.

Claim 263. (Previously Presented) A method comprising
administering a composition comprising at least one Mannich base of Claim 147 in an
amount effective for treating hyperkinetic syndrome to a person in need thereof.


Claim 264. (Previously Presented) The substituted 1- and 2-naphthol Mannich base
according to Claim 147 wherein heteroaryl in the claim is an aromatic moiety having at least
one heteroatom and is optionally substituted with halogen, CN, CF₃ or OH.

Claim 265. (Previously Presented) The substituted 1- and 2-naphthol Mannich base
according to Claim 264, wherein heteroaryl is thiophenyl, pyrrolyl or furfuryl.

Claim 266. (Previously Presented) The medicament according to Claim 201, wherein
heteroaryl in the claim is an aromatic moiety having at least one heteroatom and is optionally
substituted with halogen, CN, CF₃ or OH.

Claim 267. (Previously Presented) The medicament according to Claim 266, wherein heteroaryl is thiophenyl, pyrrolyl or furfuryl.

Claim 268. (Previously Presented) A substituted 1- and 2-naphthol Mannich base of formula I



I

wherein

$R^1 = \text{CH}(R^9) \text{N}(R^{10})(R^{11})$ and $R^2 = \text{OR}^{12}$

or

$R^1 = \text{OR}^{12}$ and $R^2 = \text{CH}(R^9) \text{N}(R^{10})(R^{11})$,

and in each case the radicals

R^3 to R^8 are identical or different and = H, F, Cl, Br, CF_3 , CN, NO_2 , SO_2NH_2 , $\text{SO}_2\text{NHR}^{13}$, NHR^{13} , SR^{15} , OR^{16} , $\text{CO}(\text{OR}^{20})$, $\text{CH}_2\text{CO}(\text{OR}^{21})$, $\text{CO}(\text{R}^{22})$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^9 denotes an aryl radical, a heteroaryl radical or an alkyl radical without an acid proton in the α -position,

R^{10} , R^{11} are identical or different and denote a branched or unbranched, saturated or unsaturated, unsubstituted or at least monosubstituted C_{1-6} -alkyl radical or an unsubstituted or at least monosubstituted phenyl, benzyl or phenethyl radical,

R^{10} and R^{11} together denote $(CH_2)_n$, wherein n is 4 or 5,

R^{12} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{13} = heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{14} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{15} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{16} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{17} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{18} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{20} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{21} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{22} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

or a racemate, enantiomer, diastereomer, a corresponding base of a physiologically tolerated acid or a corresponding salt of physiologically tolerated acid thereof,

excluding

the racemates of the compounds in which the radical $R^1 = CH(R^9) N(R^{10})(R^{11})$ and $R^2 = OR^{12}$ and in each case,

the radicals R^3 to R^8 and $R^{12} = H$, the radical R^9 = phenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 2-

fluorophenyl, 2-bromophenyl, benzo-1,3-dioxole, 4-CH₃OCO-phenyl or 2-methoxyphenyl
and the radicals R¹⁰ and R¹¹ together = (CH₂)₅,

or

the radicals R³ to R⁸ and R¹² = H, the radical R⁹ = 4-methoxyphenyl and the radicals
R¹⁰ and R¹¹ together = (CH₂)₄,

or

the radical R³ = CO(OR²⁰), the radicals R⁴ to R⁸ and R¹² = H, the radical R⁹ = phenyl,
4-methoxyphenyl, 4-methylphenyl, 4-nitrophenyl or p-benzaldehyde, the radicals R¹⁰ and R¹¹
together = (CH₂)₅ and the radical R²⁰ = CH₃,

or

the radicals R³ to R⁵, R⁷, R⁸, R¹² = H, the radical R⁶ = Br, the radical R⁹ = phenyl and
the radicals R¹⁰ and R¹¹ together = (CH₂)₅,

or

the radicals R³ to R⁸ and R¹² = H, the radical R⁹ = phenyl or 4-methoxyphenyl and the
radicals R¹⁰ and R¹¹ together = (CH₂)₅ as the hydrochloride,

or

the radical R³ = CO(OR²⁰), the radicals R⁴ to R⁸ and R¹² = H, the radical R⁹ = phenyl,
the radicals R¹⁰ and R¹¹ together = (CH₂)₅ and the radical R²⁰ = CH₃ as the hydrochloride,

and the enantiomers of the compound of formula I in which R¹ = CH(R⁹)N(R¹⁰)(R¹¹)
and R² = OR¹² and the radicals R³ to R⁸, R¹² = H, R⁹ = phenyl and R¹⁰ and R¹¹ together =
(CH₂)₅, and

the racemates of the compounds in which the radicals $R^1 = OR^{12}$ and $R^2 = CH(R^9)N(R^{10})(R^{11})$ and in each case the radicals, R^3 to R^8 and $R^{12} = H$ the radical $R^9 =$ phenyl, 2-bromophenyl, 3-bromophenyl or 4-bromophenyl and the radicals R^{10} and R^{11} together $= (CH_2)_5$,

or

R^3, R^4, R^6, R^8 and $R^{12} = H$, the radicals $R^5, R^7 = CH_3$, or $R^5 = H$ and $R^7 = CH_3$ the radical $R^9 =$ phenyl or 4-methoxyphenyl and the radicals R^{10} and R^{11} together $= (CH_2)_5$,


or

R^3 to R^6, R^8 and $R^{12} = H$, the radical $R^7 = CH_3$, the radical $R^9 =$ 4-methoxyphenyl or phenyl and the radicals R^{10}, R^{11} together $= (CH_2)_5$.

Claim 269. (Previously Presented) The medicament according to Claim 268, wherein heteroaryl in the claim is an aromatic moiety having at least one heteroatom and is optionally substituted with halogen, CN, CF_3 or OH.

Claim 270. (Previously Presented) The medicament according to Claim 269, wherein heteroaryl is thiophenyl, pyrrolyl or furfuryl.

Claim 271. (Previously Presented) A medicament comprising, at least one substituted 1- and 2-naphthol Mannich base of formula I



I

wherein

$R^1 = \text{CH}(R^9) \text{N}(R^{10})(R^{11})$ and $R^2 = \text{OR}^{12}$

or

$R^1 = \text{OR}^{12}$ and $R^2 = \text{CH}(R^9) \text{N}(R^{10})(R^{11})$,

and in each case the radicals

R^3 to R^8 are identical or different and is H, F, Cl, Br, CF_3 , CN, NO_2 , SO_2NH_2 , $\text{SO}_2\text{NHR}^{13}$, NHR^{13} , SR^{15} , OR^{16} , $\text{CO}(\text{OR}^{20})$, $\text{CH}_2\text{CO}(\text{OR}^{21})$, $\text{CO}(\text{R}^{22})$, a C_{1-10} -alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^9 denotes an aryl radical, a heteroaryl radical or an alkyl radical without an acid proton in the α -position,

R^{10} and R^{11} together denote $(\text{CH}_2)_n$, wherein n is 4 or 5,

R^{12} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{13} = heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{14} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{15} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,

R^{16} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,
 R^{17} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,
 R^{18} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,
 R^{20} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,
 R^{21} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,
 R^{22} = a heteroaryl radical or a heteroaryl radical bonded via a C_{1-6} -alkylene group,
and/or their racemates, enantiomers, diastereomers, and/or corresponding bases
and/or corresponding salts of physiologically tolerated acid and optionally further active
compounds and/or auxiliary substances.

Claim 272. (Previously Presented) The medicament according to Claim 271, wherein heteroaryl in the claim is an aromatic moiety having at least one heteroatom and is optionally substituted with halogen, CN, CF_3 or OH.

Claim 273. (Previously Presented) The medicament according to Claim 272, wherein heteroaryl is thiophenyl, pyrrolyl or furfuryl.